Target intelligence / Profile preview

GM3 ganglioside (GM3)

Target
GM3
Molecular classification
Glycosphingolipid, Ganglioside, Sialic acid-containing lipid, Lipid antigen, Other
01

Overview

GM3 ganglioside is a sialic acid-containing glycosphingolipid, classified as a ganglioside. Structurally, it consists of a ceramide lipid anchor, a lactose unit, and a terminal sialic acid; it is the simplest member of the ganglioside family and acts as the biosynthetic precursor to more complex gangliosides[1][5][7][8]. GM3 is a key component of the plasma membrane in many cell types, notably neural and immune tissues, and organizes into membrane microdomains known as lipid rafts or caveolae[5][7]. It modulates cell signaling, influencing processes like cell growth, apoptosis, immune responses, and myelin formation[3][5][7][8]. GM3's roles in pathophysiology include being a mediator and a potential therapeutic target in cancer (where it inhibits proliferation and tumor growth), autoimmunity (functioning as an autoantigen in neuropathies), metabolic diseases (modulating insulin and inflammatory signaling), and demyelinating disorders[3][4][5][7][9]. The diversity of its biological effects relates both to its structural variants (which affect fatty acid and sphingosine composition) and to its cellular context. GM3 is considered a therapeutic target for cancer and metabolic disease, though safety concerns arise from its critical physiological functions and wide tissue distribution[1][3][5][7][9]. Caveats: - There are no well-established, widely approved drugs targeting GM3 directly in clinical use; most data on interacting drugs and biomarkers is preclinical or from mechanistic studies. - GM3 is not a protein but a lipid; while frequently regarded as a "target" in the sense of immunological and pharmacological modulation, its biochemistry is distinct from receptor/drug paradigms typical for proteins.

Other names
G(M3) gangliosideGanglioside GM3HematosideII3NeuAcLacCerCHEBI:84118Monosialodihexosylganglioside[1][2][7]
02

Mechanism of action

Promotion of apoptosis through GM3 enrichment/cell signaling modulation (e.g., by cisplatin)[7]; Inhibition of growth factor receptor activity and cytokine production via plasma membrane effects[7][5]; Modulation of Toll-like receptor 4 (TLR4) signaling (pro- and anti-inflammatory effects depend on GM3 species)[4][9]; Disruption/modulation of glucose uptake via insulin receptor and caveolar interactions[5]

03

Biological functions

Modulation of cell signal transduction (including growth factor and cytokine signaling)[1][3][7][8]Regulation of cell proliferation and inhibition of cell growth[7][3]Regulation of apoptosis/cell death[7][5]Precursor for complex gangliosides[5][7][8]Modulation of immune response (including autoantigen activity)[1][3][9]Myelin formation and maintenance (oligodendrocyte maturation)[3]Organization of plasma membrane microdomains (lipid rafts/caveolae)[5]Modulation of receptor activity (e.g., insulin and TLR4 signaling)[4][9]
04

Disease associations

Cancer (involvement in cancer biology, progression, and as an anti-proliferative target)[5][7]Autoimmune neuropathies (e.g., Guillain–Barré syndrome, multiple sclerosis)[1][3]Metabolic disorders (e.g., diabetes/metabolic syndrome, insulin resistance)[4][9]Demyelinating disease[3]Sphingolipidosis (impaired ganglioside metabolism)[1][2]Inflammation (particularly chronic/metabolic inflammation)[4][9]Hearing loss (cochlear dysfunction)[5]Other
05

Safety considerations

Immunogenicity (as an autoantigen, precipitating autoimmune neuropathies)[1][3]Potential off-tumor effects in therapies targeting GM3 (given its broad tissue distribution, e.g., neural tissues)[7]Disruption of normal myelin function and hearing due to GM3 depletion or overexpression[3][5]Interference with normal immune regulation and signaling[9]
06

Interacting drugs

Cisplatin (induces GM3-mediated apoptosis in cancer cells)[7]

2 more in the full profile.

07

Biomarkers

GM3 ganglioside levels as a biomarker in serum/plasma for metabolic disorder status[4]Altered tissue/cell GM3 levels as potential marker in cancer (melanoma, breast cancer)[5]GM3 profiling for demyelination and autoimmune neuropathies[3]

Beyond the preview

Go deeper on GM3 ganglioside (GM3).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on GM3 ganglioside (GM3).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call